Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Artemether–lumefantrine (AL) and artesunate–amodiaquine (AS-AQ) are the most commonly used artemisinin-based combination therapies (ACT) for treatment of Plasmodium falciparum in Africa. Both treatments remain efficacious, but single nucleotide polymorphisms (SNPs) in the P lasmodium falciparum multidrug resistance 1 (Pfmdr1) gene may compromise sensitivity. AL and AS-AQ exert opposing selective pressures: parasites with genotype 86Y, Y184 and 1246Y are partially resistant to AS-AQ treatment, while N86, 184 F and D1246 are favoured by AL treatment. Through a systematic review, we identified 397 surveys measuring the prevalence of Pfmdr1 polymorphisms at positions 86 184 or 1246 in 30 countries in Africa. Temporal trends in SNP frequencies after introduction of AL or AS-AQ as first-line treatment were analysed in 32 locations, and selection coefficients estimated. We examined associations between antimalarial policies, consumption, transmission intensity and rate of SNP selection. 1246Y frequency decreased on average more rapidly in locations where national policy recommended AL (median selection coefficient(s) of −0.083), compared with policies of AS-AQ or both AL and AS-AQ (median s=−0.035 and 0.021, p<0.001 respectively). 86Y frequency declined markedly after ACT policy introduction, with a borderline significant trend for a more rapid decline in countries with AL policies (p=0.055). However, these trends could also be explained by a difference in initial SNP frequencies at the time of ACT introduction. There were non-significant trends for faster selection of N86 and D1246 in areas with higher AL consumption and no trend with transmission intensity. Recorded consumption of AS-AQ was low in the locations and times Pfmdr1 data were collected. SNP trends in countries with AL policies suggest a broad increase in sensitivity of parasites to AS-AQ, by 7–10 years after AL introduction. Observed rates of selection have implications for planning strategies to cycle drugs or use multiple first-line therapies to maintain drug efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“almost all genotyped samples carrying the ACT partner drug lumefantrine resistance haplotype (pfmdr1 NFD)38,39”
From Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia (2023) · cites this paper as [38]
In the citing paper
“Most of the genotyped samples carried the MDR1 NFD haplotype69–72”
From Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia (2025) · cites this paper as [69]
In the citing paper
“While the role of Y184F in lumefantrine and chloroquine susceptibility remains unclear, the 86Y allele has been linked to increased lumefantrine but reduced susceptibility to 4-aminoquinolines (amodiaquine and chloroquine)59–62, illustrating the complex interplay of drug pressures shaping resistance evolution.”
From Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia (2026) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
Goossens, H., Ferech, M., Vander Stichele, R., & Elseviers, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17907-0 · Cited by 3,359
The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015
Bhatt, S., Weiss, D. J., Cameron, E., Bisanzio, D., Mappin, B., Dalrymple, U., Battle, K. E., Moyes, C. L., Henry, A., Eckhoff, P. A., et al. (2015) · Nature · doi:10.1038/nature15535 · Cited by 3,225 · cited 2×
“Other covariates tested were the initial frequency/prevalence of the SNP at the start of the time series, antimalarial use (ACT use estimated by the Malaria Atlas Project, chloroquine use estimates from DHS, MIS and MICS surveys) and transmission intensity (measured by slide prevalence in 2–10 year olds.(42) Antimalar…”
MethodSelf-citation
Research works printed but not linked: 61
- Farooq, 2004, Drug resistance in malaria, J Vector Borne Dis, 41, 45
- 10.1038/nrdp.2017.50 · DOI · Paper page
- 10.4269/ajtmh.14-0031 · DOI · Paper page
- Thanh, 2017, Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of vietnam, Malar J, 16, 10.1186/s12936-017-1680-8 · DOI · Paper page
- 10.1038/nature12876 · DOI · Paper page
- Borrmann, 2011, Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast, PLoS One, 6, 10.1371/journal.pone.0026005 · DOI
- Tinto, 2014, Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change, Malar J, 13, 10.1186/1475-2875-13-207 · doi:10.1186/1475-2875-13-207
- Bennett, 2017, Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003-2015: a modelling study using data from national surveys, Lancet Glob Health, 5, e418, 10.1016/S2214-109X(17)30076-1 · DOI · Paper page
- 10.1038/345255a0 · DOI
- Veiga, 2016, Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies, Nat Commun, 7, 10.1038/ncomms11553 · DOI · Paper page
- 10.1016/j.febslet.2011.04.042 · DOI · Paper page
- 10.1016/S0140-6736(04)16767-6 · DOI · Paper page
- 10.1016/j.meegid.2007.03.005 · doi:10.1016/j.meegid.2007.03.005
- 10.1086/427997 · DOI · Paper page
- 10.1128/AAC.03647-14 · DOI
- 10.1128/AAC.50.5.1893-1895.2006 · DOI
- 10.1128/AAC.00875-06 · DOI · Paper page
- Otienoburu, 2016, Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia, Malar J, 15, 10.1186/s12936-016-1503-3 · doi:10.1186/s12936-016-1503-3
- Sondo, 2016, Artesunate-amodiaquine and artemether-lumefantrine therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso, PLoS One, 11, 10.1371/journal.pone.0151565 · DOI
- Dama, 2017, Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali, Malar J, 16, 10.1186/s12936-017-1700-8 · doi:10.1186/s12936-017-1700-8
- 10.1128/AAC.00638-09 · DOI · Paper page
- 10.1128/AAC.03494-14 · doi:10.1128/aac.03494-14
- 10.1093/infdis/jiu358 · DOI
- 10.1093/infdis/jis747 · DOI
- 10.1093/infdis/jiv551 · DOI
- Nguyen, 2015, Optimum population-level use of artemisinin combination therapies: a modelling study, Lancet Glob Health, 3, e758, 10.1016/S2214-109X(15)00162-X · DOI
- Baraka, 2018, Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of plasmodium falciparum multidrug resistance gene-1 polymorphisms in the democratic republic of Congo and Uganda, PLoS One, 13, 10.1371/journal.pone.0191922 · doi:10.1371/journal.pone.0191922
- 10.1128/AAC.03554-14 · doi:10.1128/aac.03554-14
- 10.4269/ajtmh.2012.12-0308 · DOI
- Okell, 2017, Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa, Sci Rep, 7, 10.1038/s41598-017-06708-9 · DOI
- 10.1093/molbev/msw228 · DOI
- 10.1073/pnas.78.10.6344 · DOI
- 10.1016/S0140-6736(03)12951-0 · DOI · Paper page
- Heisig J , Schaeffer M . It Just ain't dope to drop the slope! why you should always include a random slope for the lower-level variable of a cross-level interaction. 2018.doi:doi:10.17605/OSF.IO/BWQTD · DOI
- Bell A , Fairbrother M , Jones K , 2018. Fixed vs random effects: making an informed choice (in review). www.researchgate.net/publication/299604336 · DOI · Paper page
- Fröberg, 2012, Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar, Malar J, 11, 10.1186/1475-2875-11-321 · DOI
- 10.1111/j.1365-2958.2004.04470.x · doi:10.1111/j.1365-2958.2004.04470.x
- 10.1128/AAC.00950-12 · doi:10.1128/aac.00950-12
- 10.1086/522154 · DOI · Paper page
- 10.1093/infdis/jiq038 · doi:10.1093/infdis/jiq038
- Taylor, 2017, Artemether-lumefantrine and dihydroartemisinin-piperaquine exert inverse selective pressure on Plasmodium Falciparum drug sensitivity-associated haplotypes in Uganda, Open Forum Infect Dis, 4, 10.1093/ofid/ofw229 · doi:10.1093/ofid/ofw229
- Morris, 2015, Characterising temporal trends in asymptomatic Plasmodium infections and transporter polymorphisms during transition from high to low transmission in Zanzibar, 2005-2013, Infect Genet Evol, 33, 110, 10.1016/j.meegid.2015.04.018 · DOI
- Morris, 2015, Field deployment of loop-mediated isothermal amplification for centralized mass-screening of asymptomatic malaria in Zanzibar: a pre-elimination setting, Malar J, 14, 10.1186/s12936-015-0731-2 · DOI
- Klein, 2008, Clinically immune hosts as a refuge for drug-sensitive malaria parasites, Malar J, 7, 10.1186/1475-2875-7-67 · DOI
- Watson, 2017, Modelling the drivers of the spread of Plasmodium falciparum hrp2 gene deletions in sub-Saharan Africa, Elife, 6, 10.7554/eLife.25008 · DOI
- O'Meara, 2006, Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria, PLoS Med, 3, 10.1371/journal.pmed.0030141 · DOI
- Raman, 2008, Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique, Am J Trop Med Hyg, 78, 256, 10.4269/ajtmh.2008.78.256 · DOI
- 10.1016/S1473-3099(12)70064-6 · DOI · Paper page
- 10.4269/ajtmh.2010.09-0401 · DOI
- Huber, 2016, Quantitative, model-based estimates of variability in the generation and serial intervals of Plasmodium falciparum malaria, Malar J, 15, 10.1186/s12936-016-1537-6 · DOI
- Eyase, 2013, The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011, PLoS One, 8, 10.1371/journal.pone.0064299 · DOI
- Shah, 2015, Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya, Malar J, 14, 10.1186/s12936-015-0588-4 · doi:10.1186/s12936-015-0588-4
- 10.1128/AAC.00559-12 · DOI
- 10.1128/AAC.01894-15 · DOI
- 10.1007/s00436-012-2994-7 · doi:10.1007/s00436-012-2994-7
- Mbaye, 2016, Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal, Malar J, 15, 10.1186/s12936-016-1490-4 · DOI
- Guerra M , Neres R , Salgueiro P , et al . Plasmodium falciparum genetic diversity in continental equatorial guinea before and after introduction of artemisinin-based combination therapy. Antimicrob Agents Chemother 2017;61.doi:10.1128/AAC.02556-15 · DOI
- 10.1128/AAC.46.1.166-170.2002 · doi:10.1128/aac.46.1.166-170.2002
- 10.1073/pnas.0804628105 · DOI · Paper page
- Moser, 2018, A scalable ISFET sensing and memory array with sensor auto-calibration for on-chip real-time DNA Detection, IEEE Trans Biomed Circuits Syst, 12, 390, 10.1109/TBCAS.2017.2789161 · DOI
- Schallig, 2017, Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence, BMJ Glob Health, 2, 10.1136/bmjgh-2017-000371 · DOI
Cited by
Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia
Fola, A. A., Feleke, S. M., Mohammed, H., Brhane, B. G., Hennelly, C. M., Assefa, A., Crudal, R. M., Reichert, E., Juliano, J. J., Cunningham, J., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01461-4 · Cited by 213
Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia
Brhane, B. G., Fola, A. A., Nigussie, H., Leonetti, A., Kassa, M., Hailgiorgis, H., Wuletaw, Y., Abera, A., Mohammed, H., Sime, H., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01008-0 · Cited by 29
Letebo, A., Vanheer, L. N., Engdaw, M., Ejigu, L. A., Hailu Alemayehu, D., Deressa, J. D., Adnew, B., Ayele, A., Bezabih, M. K., Demisse, M., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02420-5 · Cited by 4
Metadata
- Authors
- Okell, L. C., Reiter, L. M., Ebbe, L. S., Baraka, V., Bisanzio, D., Watson, O. J., Bennett, A., Verity, R., Gething, P., Roper, C., & Alifrangis, M.
- Venue
- BMJ Global Health
- Publisher
- BMJ
- Published
- 2018-10
- Volume
- 3
- Issue
- 5
- Pages
- e000999
- ISSN
- 2059-7908
- Cited by
- 110
- References
- 3
- Language
- en
- Funders
- Bill and Melinda Gates Foundation
- Royal Society (Dorothy Hodgkin Fellowship)
- Medicines for Malaria Venture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa. https://app.cochat.ai/papers/10.1136/bmjgh-2018-000999
- The paper
- Okell, L. C., Reiter, L. M., Ebbe, L. S., Baraka, V., Bisanzio, D., Watson, O. J., Bennett, A., Verity, R., Gething, P., Roper, C., & Alifrangis, M. (2018). Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa. BMJ Global Health. https://doi.org/10.1136/bmjgh-2018-000999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.